SOURCE: Equity News Circuit

Equity News Circuit

May 15, 2013 08:20 ET

Free Research Reports on APOL, EW, TTWO and WX Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - May 15, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.

Apollo Group Inc. (NASDAQ: APOL) shares surged 9.05 percent on volume of 6.29 million shares traded Tuesday to close at $20.49 a share. The for-profit educator surged after CNBC reported the University of Phoenix received a letter from the HLC Institutional Actions Council recommending reaffirmation of its accreditation.

Find out more about Apollo Group including full access to the free equity report at:

Edwards Lifesciences Corp. (NYSE: EW) shares gained 6.28 percent on volume of 2.78 million shares traded to close at $71.57 a share. The company announced that its Board of Directors has approved a new $750 million share repurchase program. Shares of Edwards Lifesciences have fallen approximately 20.0 percent year-to-date.

Find out more about Edwards Lifesciences including full access to the free equity report at:

Take-Two Interactive Software, Inc. (NASDAQ: TTWO) shares spiked sharply in early trading Tuesday but settled to close at $16.54 a share, an increase of 0.91 percent. The company reported GAAP net revenue for the fourth quarter of fiscal 2013 grew to $299.5 million from $148.1 million a year ago.

Find out more about Take-Two Interactive Software including full access to the free equity report at:

WuXi PharmaTech Inc. (NYSE: WX) shares increased 2.0 percent on more than double the average daily volume Tuesday to close at $20.40 a share. The company reported revenues of $131.9 million for the first quarter of 2013, an increase of 11.7 percent when compared to the year ago quarter.

Find out more about WuXi PharmaTech including full access to the free equity report at:

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information